Petrelintide Dosing Guide: Once-Weekly Amylin Analog Titration
Petrelintide dosage explained from Roche/Zealand Phase 2 ZUPREME-1: once-weekly subcutaneous amylin analog, escalated every 4 weeks across five dose arms, with up to ~10.7% weight loss at 42 weeks.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Log your dosing protocol in PeptIQ
Turn this guide into a living protocol — doses, vials, and history in one place.
Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist
# Petrelintide Dosing Guide: Once-Weekly Amylin Analog Titration
> Note: PeptIQ is not a medical provider. Petrelintide is investigational. Exact milligram labels for all Phase 2 arms may remain partially masked in topline releases — do not invent DIY doses from forum posts. Educational content only.
Petrelintide is a long-acting human amylin analog from Roche/Genentech and Zealand Pharma. It sits in the same strategic lane as cagrilintide and eloralintide: weekly satiety biology that is related to, but distinct from, GLP-1.
Quick Answer: How Is Petrelintide Dosed?
From public ZUPREME-1 communications:
Design element
What was tested
Route
Subcutaneous
Cadence
Once weekly
Arms
Five active dose levels + placebo
Escalation
Dose increased about every 4 weeks
Primary efficacy window highlighted
Weight change at week 28 (all arms beat placebo)
Longer readout
Through week 42, with additional follow-up planned for congress presentation
Topline coverage has emphasized efficacy and tolerability more than publishing a full public milligram table for every arm. Until the full congress dataset posts dose-by-dose mg, treat "five weekly arms + q4w escalation" as the accurate dosing vocabulary.
ZUPREME-1 Results Snapshot
ZUPREME-1 enrolled 493 adults with overweight or obesity (mean BMI ~37), in a relatively gender-balanced cohort, on lifestyle counseling plus weekly petrelintide or placebo.
Public ADA / Healio-style summaries reported:
Clinically meaningful weight loss in every active arm vs placebo at the primary 28-week analysis
At 42 weeks, weight loss up to about 10.7% at the highest petrelintide dose vs about 1.7% placebo
Investigators highlighted a very well tolerated profile relative to typical GLP-1 expectations in early commentary
That combination — solid double-digit loss with a tolerability narrative — is why petrelintide searches are climbing beside eloralintide and CagriSema.
Why Escalation Every 4 Weeks Matters
Amylin agonists share a GI / early-fullness risk with incretins. A four-week step schedule is the same titration philosophy that works for orforglipron and many GLP-1 labels:
Start low enough to adapt
Hold each step long enough to read nausea and meal-size collapse
Only then climb
Protect protein and training the whole way
If you are building a tracking template for any future labeled amylin analog, copy that cadence into your log even before milligrams are public.
Petrelintide's near-term differentiator in media coverage is tolerability positioning, not "highest percent loss at all costs."
Pipeline Next Steps to Watch
Full ZUPREME-1 dose tables + body-composition secondary endpoints at congress
ZUPREME-2 topline in obesity/overweight with type 2 diabetes (expected later in 2026 per Roche)
Phase 2 combo exploration with CT-388 (Roche incretin asset) later in 2026
Combo work is the stacking SEO angle: amylin + incretin, same thesis as CagriSema / eloralintide add-on trials.
What to Track
Weekly injection day
Escalation week number (every 4th week logic)
Nausea / early fullness scores for 72 hours post-dose
Protein grams and lifting sessions
7-day average weight + waist
Reasons for holds (GI, travel, plateau review)
FAQ
Q: What is the standard petrelintide dose?
A: There is no approved consumer dose. Phase 2 used five once-weekly dose levels with escalation about every four weeks. Exact mg per arm should be taken from the full peer-reviewed / congress tables when published.
Q: How much weight loss does petrelintide cause?
A: Public ZUPREME-1 summaries cite up to ~10.7% mean loss at 42 weeks at the highest dose vs ~1.7% placebo. Individual results vary.
Q: Is petrelintide a GLP-1?
A: No. It is an amylin analog. It may feel "GLP-1-like" in appetite effects, but the receptor biology differs.
Q: Can I buy petrelintide as a research peptide?
A: Treat gray-market labels as high-risk and non-equivalent to clinical trial product. Evidence tier and legality first.
Bottom Line
Petrelintide dosing in 2026 public science means: once-weekly SC amylin analog, five Phase 2 dose arms, escalation about every four weeks, and up to ~10.7% mean weight loss at 42 weeks with a strong tolerability narrative. Log the titration logic now; fill milligrams from primary sources when they publish.
Download PeptIQ to track weekly amylin-style protocols with symptom scores.
